Should you find a link that does not work within any Guidance document, Rule or other document posted on the FDA Web site, please try searching for the document using the document title. If you need further assistance, please go to Contact FDA.

---

• Policy for Certain REMS Requirements During the Tocilizumab Shortage Related to the COVID-19 Public Health Emergency; Guidance for Industry and Health Care Professionals
  12/2021

• Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations; Guidance for Industry
  9/2021

• Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial; Draft Guidance for Industry
  9/2021

• Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency; Guidance for Industry
  1/2021

• Human Gene Therapy for Neurodegenerative Diseases; Draft Guidance for Industry
  1/2021

• Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry
  1/2020

• Long Term Follow-up After Administration of Human Gene Therapy Products; Guidance for Industry
  1/2020

• Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry
  1/2020

• Human Gene Therapy for Hemophilia; Guidance for Industry
  1/2020

• Human Gene Therapy for Rare Diseases; Guidance for Industry
  1/2020

• Human Gene Therapy for Retinal Disorders; Guidance for Industry
  1/2020

• Evaluation of Devices Used with Regenerative Medicine Advanced Therapies; Guidance for Industry
  2/2019

• Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Guidance for Industry
  2/2019

• Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff
  Updated: 12/2017

• Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception; Guidance for Industry
  11/2017

• Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271; Guidance for Industry
  9/2017

• Recommendations for Microbial Vectors Used for Gene Therapy; Guidance for Industry
  9/2016

• Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products; Guidance for Industry
  8/2015

• Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Guidance for Industry
  6/2015

• Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products; Guidance for Industry
  3/2015

• Guidance for Industry: BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System
  3/2014. (This guidance finalizes the draft guidance of the same title dated June 2013.)

• IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System - Guidance for Industry and FDA Staff
  3/2014. (This guidance finalizes the draft guidance of the same title dated June 2013.)

• Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products
  (This guidance finalizes the draft guidance entitled “Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products” dated November 2012) 11/2013

• Guidance for Industry: Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage
  12/2011. (This guidance finalizes the draft guidance of the same title dated July 2007.)

• Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines
  10/2011. (This guidance finalizes the draft guidance of the same title dated September 2009.)

• Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products
  1/2011. (This guidance finalizes the draft document of the same name, dated October 2008.)

• Guidance for Industry: Cellular Therapy for Cardiac Disease
  (This guidance finalizes the draft guidance entitled “Guidance for Industry: Somatic Cell Therapy for Cardiac Disease” dated March 2009 (April 2, 2009, 74 FR 14992). 10/2010.

• Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products
  9/2009

• Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)
  4/2008

• Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry
  8/2007

• Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy
  3/1998